# AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy

> **NCT00102336** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 62 (actual)

## Conditions studied

- Thrombocytopenia
- Idiopathic Thrombocytopenic Purpura

## Interventions

- **BIOLOGICAL:** AMG 531
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00102336
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04-07
- **Primary completion:** 2006-12-01
- **Final completion:** 2007-04-01
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2022-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00102336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00102336, "AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00102336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*